Highlights 3SBio Inc.

Equities

1530

KYG8875G1029

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 08:08:04 06/02/2026 GMT			5-day change	1st Jan Change
22.94 ^HKD	-0.78%		-1.55%	-5.13%

12-02	3SBio Seeks HK$3.12 Billion via Share Sale	MT
12-02	3SBio to place 105.2 million shares	RE

Highlights

11-21	3SBio Proposes Spinoff, Hong Kong Listing of Unit Mandi	MT
11-20	3SBio proposes spin-off and listing of Mandi Inc. on HKSE	RE
11-19	3SBio Inc. agreed to Spin-Off unknown minority stake in Mandi Inc.	CI
29/08/25	3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
29/08/25	3SBio's Profit Jumps 25% in H1	MT
29/08/25	3SBio posts H1 gross margin of 85.3%	RE
29/08/25	Tranche Update on 3SBio Inc.'s Equity Buyback Plan announced on June 25, 2024.	CI
05/08/25	Pfizer raises 2025 profit forecast as cost-cutting program gains traction	RE
24/07/25	Pfizer Inc. Completes Licensing Agreement with 3SBio, Inc	CI
25/06/25	3SBio Inc. Declares Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 2025	CI
20/05/25	Pfizer Strikes up to $6.05 Billion Licensing Deal for 3SBio's Cancer Drug Candidate	MT
20/05/25	Pfizer Signs Licensing Deal With China's 3SBio for Cancer Treatment Candidate	MT
20/05/25	Hong Kong Stocks Rise as China Cuts Interest Rates; CATL Jumps 16% in Debut	MT
30/04/25	Tranche Update on 3SBio Inc.'s Equity Buyback Plan announced on June 25, 2024.	CI
18/04/25	3SBio's Lung Cancer Drug Gets Breakthrough Therapy Designation in China	MT
17/04/25	3Sbio Says 707 Injection (Anti-Vegf/Pd-1 Bispecific Antibody) Granted Breakthrough Therapy Designation By NMPA	RE
17/04/25	3SBio Inc. Receives Breakthrough Therapy Designation by China's National Medical Products Administration	CI
26/03/25	3SBio's 2024 Profit Jumps 35%	MT
25/03/25	3SBIO Announces Final Dividend Of HKD25 Cents Per Share	RE
25/03/25	3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2024, Payable on August 15, 2025	CI
25/03/25	3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2024, Payable on 15 August 2025	CI
25/03/25	3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
13/01/25	3SBio Unit Gets Commercialization Rights for Duality Biologics' Cancer Drug in China, Hong Kong, Macau	MT
18/12/24	3SBio Cancels All Treasury Shares	MT
26/11/24	3SBio's Unit Gets Exclusive Commercialization Rights for Clifutinib Besylate in Mainland China	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

3SBio stock surges after acquiring licensing rights to cancer drug

March 21, 2025 at 06:49 am